APA (7th ed.) Citation

Takano, H., Sakamoto, J., Sakamaki, H., Kimura, S., Hino, M., Hashino, S., . . . Iriyama, N. (2018). The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. Internal Medicine, 57(1), 17-23. https://doi.org/10.2169/internalmedicine.9035-17

Chicago Style (17th ed.) Citation

Takano, Hina, et al. "The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group." Internal Medicine 57, no. 1 (2018): 17-23. https://doi.org/10.2169/internalmedicine.9035-17.

MLA (9th ed.) Citation

Takano, Hina, et al. "The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group." Internal Medicine, vol. 57, no. 1, 2018, pp. 17-23, https://doi.org/10.2169/internalmedicine.9035-17.